A controlled trial on uterine adenomyosis treatment comparing aromatase inhibitor plus gnrh analogue versus dienogest in women undergoing IVF

Marco Sbracia; Fabio Scarpellini

doi:10.1016/j.fertnstert.2018.07.252

A controlled trial on uterine adenomyosis treatment comparing aromatase inhibitor plus gnrh analogue versus dienogest in women undergoing IVF

Marco Sbracia, Fabio Scarpellini

In: Fertility and Sterility · 2018 · vol. 110(4) , pp. e83–e84 · doi:10.1016/j.fertnstert.2018.07.252 · W2892023716

article OA: bronze CC0 ⤵ 1 in-corpus citation

🔓 Open OA copy View on OpenAlex View at publisher

⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This controlled trial investigated the efficacy of aromatase inhibitor plus GnRH analogue versus dienogest for treating uterine adenomyosis in women undergoing IVF.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

adenomyosis

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

Adenomyosis in infertile women: prevalence and the role of 3D ultrasound as a marker of severity of the disease 2016

Cited by (1)

The use of dienogest in treatment of symptomatic adenomyosis: A systematic review and meta-analysis 2024

References (1)

Adenomyosis in infertile women: prevalence and the role of 3D ultrasound as a marker of severity of the disease via openalex

Cited by (1)

The use of dienogest in treatment of symptomatic adenomyosis: A systematic review and meta-analysis 2024

Source provenance

openalex: last seen: 2026-06-10T17:14:06.276822+00:00

License: CC0 · commercial use OK

[1] Adenomyosis in infertile women: prevalence and the role of 3D ultrasound as a marker of severity of the disease 2016